Sei Investments Company Trimmed Its Holding in Alnylam Pharmaceuticals (ALNY) as Shares Declined; Lowes Cos (LOW) Holder Virtu Financial Has Trimmed Its Stake

June 13, 2018 - By Marguerite Chambers

Lowe's Companies, Inc. (NYSE:LOW) Logo

Virtu Financial Llc decreased its stake in Lowes Cos Inc (LOW) by 87.29% based on its latest 2018Q1 regulatory filing with the SEC. Virtu Financial Llc sold 16,866 shares as the company’s stock declined 0.84% with the market. The institutional investor held 2,456 shares of the consumer services company at the end of 2018Q1, valued at $216,000, down from 19,322 at the end of the previous reported quarter. Virtu Financial Llc who had been investing in Lowes Cos Inc for a number of months, seems to be less bullish one the $82.02B market cap company. It closed at $100.5 lastly. It is down 18.89% since June 13, 2017 and is uptrending. It has outperformed by 6.32% the S&P500. Some Historical LOW News: 19/05/2018 – Fixing Up Lowe’s — Barron’s; 24/05/2018 – Lowe’s to Webcast Annual Meeting of Shareholders; 23/05/2018 – Ackman Takes Roughly $1 Billion Stake in Lowe’s -Update; 06/03/2018 – RBA’S LOWE: PROGRESS ON UNEMPLOYMENT AND INFLATION LIKELY TO BE ONLY GRADUAL; 22/05/2018 – J.C. Penney CEO Quits to Join Lowe’s; 04/05/2018 – Moody’s Affirms Nine Classes of CGCMT 2016-C1; 05/03/2018 Lowe’s to Webcast Presentation from the UBS Global Consumer & Retail Conference; 14/05/2018 – Dodge & Cox Adds GCI Liberty Inc., Exits Lowe’s: 13F; 06/03/2018 – LOWE: LOWER CURRENCY WOULD HELP INFLATION, UNEMPLOYMENT; 30/03/2018 – US News: Negative Sentiment May Be Positive for Lowe’s

Sei Investments Company decreased its stake in Alnylam Pharmaceuticals Inc (ALNY) by 34.07% based on its latest 2018Q1 regulatory filing with the SEC. Sei Investments Company sold 16,754 shares as the company’s stock declined 18.72% with the market. The institutional investor held 32,422 shares of the health care company at the end of 2018Q1, valued at $3.86 million, down from 49,176 at the end of the previous reported quarter. Sei Investments Company who had been investing in Alnylam Pharmaceuticals Inc for a number of months, seems to be less bullish one the $10.65 billion market cap company. The stock increased 5.86% or $5.86 during the last trading session, reaching $105.91. About 811,352 shares traded. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has risen 43.86% since June 13, 2017 and is uptrending. It has outperformed by 31.29% the S&P500. Some Historical ALNY News: 26/04/2018 – Alnylam to Webcast Conference Call Discussing First Quarter 2018 Financial Results; 21/03/2018 – Regeneron and Alnylam Pharmaceuticals Announce Collaboration to Discover New Treatments for Nonalcoholic Steatohepatitis (NASH); 03/04/2018 – SILENCE THERAPEUTICS PLC SLN.L SAYS BROUGHT PATENT INFRINGEMENT PROCEEDINGS IN PORTUGAL AGAINST ALNYLAM’S PATISIRAN PRODUCT; 03/05/2018 – ALNYLAM PHARMACEUTICALS INC – CO AND FDA HAVE ALIGNED ON A STUDY SIZE OF APPROXIMATELY 25 PATIENTS WITH PH1; 28/03/2018 – #EASL2018 late breakers still embargoed for official press program $CBAY PPARδ Ph2 PBC $NVS FXR Ph2 PBC @NGMBio FGF19 Ph2 PSC $ALNY Givosiran in AIP; 29/03/2018 – Whoa, $ALNY -7% And from the PM bureau, @BrittanyMeiling has this: Watch out Alnylam/Ionis: Pfizer’s positive PhIII tafamidis data makes drug a new rival; 20/04/2018 – ALNYLAM PHARMACEUTICALS – ALL OTHER SETTLEMENT TERMS ARE CONFIDENTIAL; 03/05/2018 – Alnylam Intends to Initiate Lumasiran Phase 3 Study in Mid-2018; 12/03/2018 – Busy Sanofi takes a pass on one of Alnylam’s rare disease drugs, FDA offers ‘breakthrough’ status for PhIII $SNY $ALNY; 03/05/2018 – ALNYLAM SEES TOPLINE RESULTS IN ’19

Virtu Financial Llc, which manages about $1.86B US Long portfolio, upped its stake in New Oriental Ed Tech Grp I (NYSE:EDU) by 3,930 shares to 9,805 shares, valued at $859,000 in 2018Q1, according to the filing. It also increased its holding in Etf Ser Solutions by 29,122 shares in the quarter, for a total of 40,956 shares, and has risen its stake in Proshares Tr (DIG).

Among 37 analysts covering Lowe’s Companies Inc. (NYSE:LOW), 24 have Buy rating, 0 Sell and 13 Hold. Therefore 65% are positive. Lowe’s Companies Inc. had 102 analyst reports since August 19, 2015 according to SRatingsIntel. The stock has “Market Perform” rating by Telsey Advisory Group on Thursday, December 8. The company was maintained on Tuesday, October 31 by Robert W. Baird. The rating was maintained by Guggenheim with “Buy” on Wednesday, February 28. Credit Suisse maintained the shares of LOW in report on Monday, March 5 with “Buy” rating. On Thursday, November 19 the stock rating was maintained by RBC Capital Markets with “Outperform”. The company was upgraded on Monday, January 22 by Bernstein. BMO Capital Markets maintained the shares of LOW in report on Friday, March 2 with “Market Perform” rating. The firm has “Outperform” rating given on Wednesday, January 24 by Robert W. Baird. The firm has “Neutral” rating given on Monday, October 31 by PiperJaffray. Longbow maintained Lowe's Companies, Inc. (NYSE:LOW) rating on Friday, August 14. Longbow has “Buy” rating and $85 target.

Investors sentiment decreased to 0.81 in 2018 Q1. Its down 0.20, from 1.01 in 2017Q4. It worsened, as 72 investors sold LOW shares while 482 reduced holdings. 116 funds opened positions while 331 raised stakes. 587.47 million shares or 0.28% more from 585.84 million shares in 2017Q4 were reported. Vident Investment Advisory Limited Liability Corporation stated it has 0.01% of its portfolio in Lowe's Companies, Inc. (NYSE:LOW). Holderness Investments owns 13,227 shares for 0.57% of their portfolio. Beck Management Limited Liability reported 3,160 shares. Verition Fund Management Lc holds 0.06% in Lowe's Companies, Inc. (NYSE:LOW) or 9,303 shares. 74,266 were accumulated by Commonwealth Of Pennsylvania Public School Empls Retrmt. Stratos Wealth Prns Limited holds 0.22% of its portfolio in Lowe's Companies, Inc. (NYSE:LOW) for 59,531 shares. Teacher Retirement Systems Of Texas invested in 0.14% or 233,290 shares. 29,135 were accumulated by Pacific Investment Mngmt Co. Mcdaniel Terry has 0.04% invested in Lowe's Companies, Inc. (NYSE:LOW) for 2,396 shares. Edge Wealth Mgmt Ltd Co invested 0% of its portfolio in Lowe's Companies, Inc. (NYSE:LOW). Roberts Glore & Il holds 0.21% of its portfolio in Lowe's Companies, Inc. (NYSE:LOW) for 3,890 shares. Geode Cap Management Limited Liability Corp reported 9.54 million shares. Aristotle Cap Management Ltd stated it has 0.27% of its portfolio in Lowe's Companies, Inc. (NYSE:LOW). Stone Ridge Asset Ltd Company has invested 0.18% in Lowe's Companies, Inc. (NYSE:LOW). Spears Abacus Ltd Company reported 5,728 shares.

Analysts await Lowe's Companies, Inc. (NYSE:LOW) to report earnings on August, 22. They expect $2.01 earnings per share, up 28.03% or $0.44 from last year’s $1.57 per share. LOW’s profit will be $1.64B for 12.50 P/E if the $2.01 EPS becomes a reality. After $1.19 actual earnings per share reported by Lowe's Companies, Inc. for the previous quarter, Wall Street now forecasts 68.91% EPS growth.

More notable recent Lowe's Companies, Inc. (NYSE:LOW) news were published by: Fool.com which released: “JC Penney’s CEO Jumps to Lowe’s: Is the Turnaround Doomed?” on May 27, 2018, also Seekingalpha.com with their article: “Does Lowe’s Deserve A Second Chance?” published on May 24, 2018, Fool.com published: “Why Did Lowe’s Companies, Inc. Shares Gain 15% in May?” on June 12, 2018. More interesting news about Lowe's Companies, Inc. (NYSE:LOW) were released by: Fool.com and their article: “What Lowe’s Wants You to Know About Its Latest Results” published on May 31, 2018 as well as Bizjournals.com‘s news article titled: “Lowe’s to lose a second C-level executive” with publication date: June 04, 2018.

Sei Investments Company, which manages about $26.09B US Long portfolio, upped its stake in Cincinnati Finl Corp (NASDAQ:CINF) by 8,640 shares to 59,506 shares, valued at $4.42 million in 2018Q1, according to the filing. It also increased its holding in Delek Us Hldgs Inc New by 75,650 shares in the quarter, for a total of 75,772 shares, and has risen its stake in Exact Sciences Corp (NASDAQ:EXAS).

More notable recent Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) news were published by: Fool.com which released: “Better Buy: Bellicum Pharmaceuticals, Inc. vs. Alnylam Pharmaceuticals, Inc.” on June 03, 2018, also Fool.com with their article: “Is Alnylam Pharmaceuticals, Inc. (ALNY) a Buy?” published on May 17, 2018, Seekingalpha.com published: “Eidos Therapeutics files for initial public offering” on May 25, 2018. More interesting news about Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) were released by: Seekingalpha.com and their article: “Alnylam Pharmaceuticals Continues To Develop Options Outside Of Amyloidosis” published on June 12, 2018 as well as Seekingalpha.com‘s news article titled: “Akcea And Ionis: What The Latest Regulatory Catalyst For Inotersen Foretells” with publication date: June 08, 2018.

Analysts await Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to report earnings on August, 8. They expect $-1.71 EPS, down 27.61% or $0.37 from last year’s $-1.34 per share. After $-1.41 actual EPS reported by Alnylam Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 21.28% negative EPS growth.

Among 24 analysts covering Alnylam Pharmaceuticals (NASDAQ:ALNY), 17 have Buy rating, 1 Sell and 6 Hold. Therefore 71% are positive. Alnylam Pharmaceuticals had 108 analyst reports since August 7, 2015 according to SRatingsIntel. BMO Capital Markets maintained it with “Buy” rating and $160.0 target in Thursday, February 8 report. On Thursday, September 7 the stock rating was maintained by Piper Jaffray with “Buy”. The rating was maintained by Morgan Stanley on Thursday, August 10 with “Equal-Weight”. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has “Hold” rating given on Thursday, October 6 by Stifel Nicolaus. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has “Hold” rating given on Friday, May 4 by Stifel Nicolaus. Piper Jaffray maintained Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) rating on Thursday, March 22. Piper Jaffray has “Buy” rating and $182.0 target. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) earned “Buy” rating by Needham on Thursday, February 9. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) earned “Outperform” rating by Credit Suisse on Wednesday, January 20. The firm earned “Buy” rating on Tuesday, July 11 by Cowen & Co. Credit Suisse maintained it with “Outperform” rating and $50 target in Thursday, October 6 report.

Investors sentiment decreased to 1.4 in 2018 Q1. Its down 0.63, from 2.03 in 2017Q4. It dropped, as 25 investors sold ALNY shares while 67 reduced holdings. 43 funds opened positions while 86 raised stakes. 89.26 million shares or 1.02% less from 90.18 million shares in 2017Q4 were reported. Principal Fincl Group Inc Inc Inc reported 24,525 shares. Goldman Sachs holds 0.03% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 1.01M shares. 28,185 are held by Fjarde Ap. Emory University holds 1.81% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 21,316 shares. Aperio Ltd Liability invested 0.01% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Hall Laurie J Trustee owns 3,800 shares or 0.28% of their US portfolio. Architects Inc holds 0% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) or 140 shares. Mackenzie invested in 17,265 shares or 0.01% of the stock. Point72 Asset Management LP holds 0.45% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 908,046 shares. Credit Suisse Ag has invested 0.03% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Pub Employees Retirement Sys Of Ohio reported 36,825 shares. Ser Automobile Association invested in 0.02% or 57,486 shares. Brown Brothers Harriman & Com holds 0% or 15 shares in its portfolio. Aqr Capital Llc has invested 0% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Magnetar Lc accumulated 4,603 shares.

Since January 4, 2018, it had 0 insider purchases, and 11 sales for $39.55 million activity. KEATING LAURIE sold 20,000 shares worth $2.90M. The insider SCHIMMEL PAUL sold $4.17 million. $2.57 million worth of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shares were sold by Ausiello Dennis A. Vaishnaw Akshay sold 88,554 shares worth $12.67 million. $5.50M worth of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) was sold by Greene Barry E. CLARKE JOHN K sold $1.50M worth of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on Thursday, May 31.

Lowe's Companies, Inc. (NYSE:LOW) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>